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Tracking the Growth of Brain Metastases
Benjamin Ciccarelli, Gregory J. Kubicek, MD, Alan Turtz, MD, Piya Saraiya, MD, Howard Warren
Goldman, MD
Background: Literature is relatively sparse on the growth rate of brain metastases. This is an important
concept, given that the time delay between imaging and treatment may result in clinically significant
tumor growth that could alter treatment planning. Understanding the growth rate of brain metastases is
also useful in determining the value of radiation therapy for poor performance patients. This study will
potentially shed light on this subject and spur further research.
Methods: This qualitative study includes 21 patients treated with Gamma Knife therapy at MD Anderson
of Cooper University Hospital. These 21 patients had various amounts of brain metastases, totaling 38
metastases. All patients had never received SRS or chemotherapy in the past or during the timeframe
between imaging to treatment. All patients had 2 MRI imaging sets. Imaging sets were retrospectively
reviewed to measure volume, size of greatest dimension, and type of lesions.
Results: By size of greatest dimension, our data for all masses revealed a growth rate of 0.12mm/day (SD
± 0.23). solid lesions at 0.12mm/day (SD ± 0.17), necrotic lesions at 0.13mm/day (SD ± 0.25), and cystic
lesions at 0.05mm/day. When studying growth rate in volume, all masses had an average growth rate at
0.03mL/day (SD ± 0.06), solid lesions at 0.02mL/day (SD ± 0.07), necrotic lesions at 0.04mL/day (SD ±
0.04), and cystic lesions at 0.02mL/day.
Conclusion: Our results show growth between imaging sets that may have clinical significance for SRS
treatment planning. Further research should be done into this subject to optimize delivery of radiation
treatment.
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Introduction
Brain metastases are the most common type of intracranial tumor in adults, occurring with much
greater frequency than primary brain tumors.1 Evidence suggests that the incidence of brain metastases
may be increasing, although this could be secondary to a larger elderly population and more advanced
imaging modalities leading to greater detection.2 There is also evidence that advances in chemotherapy
may be responsible for the increased incidence of brain metastases, as these tumors may only become
clinically apparent after a patient’s life is prolonged via chemotherapy.2 In adults, the most common
primary malignancies in those with brain metastases include lung cancer, followed by melanoma, renal,
breast, and colorectal cancers.3
Hematogenous spread is the most common route of delivery from site of primary malignancy to
the brain.4 After traveling through the blood, cancer cells most often deposit at the gray and white matter
junction.5,6 The distribution of brain metastases positively correlates with the amount of blood flow. This
results in most brain metastases residing in the cerebral hemispheres, followed by the cerebellum and
brainstem.5,6 For unknown reasons, some primary malignancies tend to metastasize in particular regions
of the brain.5,6
It is difficult to determine the precise incidence rate of brain metastases. While it is estimated that
approximately 21,000 to 43,000 patients are diagnosed each year with brain metastases using census data,
autopsy suggests that the incidence rate may lie over 100,000.7 This discrepancy may be due to the
variability in symptomatology in those with brain metastases, allowing many to go undiagnosed. 7 Many
different statistical models have been developed to help determine the incidence rate, however no
universal consensus has been reached.7
Brain metastases can cause a large variety of clinical presentations, from mild to devastating. This
can include headache, neurologic deficits, cognitive dysfunction, seizures, and stroke.6,8 Headache is the
most common presentation, and typically presented as a tension headache.9 This often presented with
other symptoms, such as worsening with position and nausea and vomiting.9 Although early morning
headaches are more specific for brain tumors, they are much less common.9
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Mortality in those diagnosed with brain metastases is high. Hall et al’s10 research was aimed at
determining the incidence of long-term survival for patients with brain metastases (defined as ≥2 years).
They compared long-term survival between varying primary cancers. They found that the long-term
survival rate in these patients was dependent on their primary cancer type.10 Of note, only 18% of patients
died of central nervous system progression, while 57% died of systemic disease progression.10 This
demonstrates that most patients with brain metastases do not die from these lesions themselves, and this is
important when determining management for poor performance patients.
Magnetic resonance imaging (MRI) has become the predominant imaging modality to diagnose
brain tumors.6,11,12 While computed tomography (CT) scan and non-contrast MRI can be used, they are
not as sensitive as contrast-enhanced MRI.6,11,12 When contrast-enhanced MRI is used, brain metastases
can often be distinguished from other types of brain tumors, which ultimately helps to determine the next
step in management.6,12 Defining characteristics of brain metastases include: multiple tumors, distribution
at the junction of the grey and white matter, circumscribed margins, excess vasogenic edema surrounding
the tumor.6 If it is too difficult to establish a clear diagnosis of brain metastasis through imaging, biopsy
can be performed.6 If brain metastasis is proven through biopsy and the primary tumor is not known, it is
most prudent to investigate the lung, since lung cancer is the most common primary tumor producing
brain metastases in the United States.6
Multiple treatment modalities have been established for the treatment of brain metastases,
including chemotherapy that readily crosses the blood-brain barrier, Gamma Knife and Cyberknife (both
of which fall under the umbrella term stereotactic radiosurgery), whole brain radiation therapy (WBRT),
and neurological surgery.13 Gamma Knife and Cyberknife offer a strong and focused dose of radiation to
specific areas of the brain, minimizing the damage to surrounding structures and minimizing neurological
complications.13 This tends to be more beneficial when metastases are clearly identifiable and are not too
numerous.13 WBRT is useful when there are numerous brain metastases, with many that are likely present
but unable to be clearly identifiable on imaging. WBRT increases the risk of neurologic complications
relative to stereotactic radiosurgery, as it is not as specific in its administration of radiation when
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compared to SRS.13 However, because it acts more diffusely, it can provide radiation to multiple brain
metastases both seen and not yet seen on imaging.14
There is strong evidence supporting the use of stereotactic radiosurgery for brain metastases. For
example, Magnuson et al’s15 research on the appropriate time to use radiation therapy relative to
chemotherapy treatment supports the use of early radiation therapy. Their study analyzed 202 patients
who were diagnosed with non-small cell lung carcinoma (NSCLC) and found to have an epidermal
growth factor receptor (EGFR) mutation. Their results suggested that the deferral of local radiation
therapies in patients with NSCLC and EGFR mutation receiving tyrosine kinase inhibitors (TKI) had
inferior overall survival compared to patients who received local radiation therapy and TKI upfront.14
SRS is largely dependent on imaging to guide treatment decision-making. While abundant
research has been done on these different modalities, literature is relatively sparse on the growth rate of
brain metastases. This is important, given that the time delay between imaging and delivery of treatment
may result in clinically significant tumor growth that could alter treatment planning.
This study of growth rate in brain metastases is particularly relevant in therapies such as
Cyberknife, where treatment planning may be based on imaging obtained >1 week before treatment
administration. This contrasts with Gamma Knife therapy, where a pretreatment MRI is always obtained
within hours of treatment. The understanding of growth rate in brain metastases can increase the
confidence of radiation oncologists on the effects of delay in treatment, and potentially provide ways in
which they can compensate and account for tumor growth during this time frame, such as a compensatory
increase in the treatment margins surrounding the brain tumor.
As of this time, there are no current recommendations for imaging to treatment delay. Seymour et
al’s16 research attempted to determine the length of time from imaging to treatment that is appropriate.
This study included 82 patients and 151 brain metastases evaluated for. They found that local freedom
from progression (LFFP) remained significantly lower for lesions with a delay in treatment from imaging
at a period of ≥14 days.16 They described that ideally the treatment delay would be less than 14 days,
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however, at this time this works as a starting point in determining the optimal delay in radiation
treatment.16
Understanding the growth rate of brain metastases is also useful in determining the value of
radiation therapy for poor performance patients. For example, a patient with brain metastases who has a
poor prognosis may not benefit from radiation therapy if it is determined that their tumor growth will not
be significant in their lifetime. This may provide an improved quality of life (QOL) for those patients who
otherwise may have suffered from complications of radiation therapy.
We hypothesize that the masses will not outgrow a 2-mm expansion of margins from initial
diagnostic MRI to pre-treatment (Gamma knife) MRI. Patients who received Gamma Knife therapy were
chosen to be reviewed given the necessity of requiring 2 MRI imaging sets prior to treatment: 1 set at
diagnosis and a 2nd imaging set pre-treatment, which allowed for simple and consistent comparison. Our
goals of the study are also to determine a general growth rate for brain metastases to address the
aforementioned uncertainties of delay of treatment and determine the value of radiation therapy in poor
performance patients.
Methods
This study includes 21 patients treated with Gamma Knife therapy at MD Anderson of Cooper
University Hospital throughout years 2015-2016. These 21 patients had varying amounts of brain
metastases, with a total of 38 metastases. All patients had never received SRS in the past or during the
timeframe between imaging to treatment. No patients were receiving chemotherapy during this
timeframe. All patients, excluding one, had 2 imaging sets: 1 diagnostic MRI and 1 pre-Gamma Knife
therapy MRI. One patient had a total of 3 imaging sets due to a large delay in receiving radiation
treatment after diagnosis, necessitating a repeat MRI. All MRI imaging results were reviewed using
Pinnacle software.
Size of greatest dimension was measured for each tumor on diagnostic MRI and pre-treatment
MRI. Size of volume was also measured. This was mainly performed by one researcher to maintain
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consistency in measurements, with collaboration only on difficult cases to ensure accuracy of
measurement.
A 2-mm expansion was also placed around each tumor in diagnostic MRI. This 2-mm expansion
was then viewed on the pre-treatment MRI to determine if the lesion had outgrown the expansion. This
was to observe if enough coverage could be attained with expansion of the lesion on diagnostic MRI to
base adequate radiation treatment on.
Results
The mean number of brain metastases observed per patient in this study was 1.69 (SD ± 1.17)
lesions. 8 of the patients observed had multiple metastasis on MRI, while the others had 1 singular lesion.
The patient with the most brain metastases studied had a total of 6 lesions.
MRI images were analyzed using Pinnacle software, and the types of tumors were classified as
either being solid, cystic, or necrotic. 24 of the lesions observed were solid, making up 64.1% of tumors
observed. 13 lesions were necrotic, making up 34.2% of tumors observed. 1 lesion was cystic, making up
2.63% of tumors observed. Table A includes our collected data for each type of tumor.
Our collected data had a mean time span from diagnostic MRI to pre-treatment MRI of 20.39
days (SD ± 16.54). In this time, the size of greatest dimension increased from a mean of 1.23cm (SD ±
0.73) to a mean of 1.45 (SD ± 0.71). In volume, masses grew from a mean of 1.27mL (SD ± 1.92) to a
mean of 1.92 (SD ± 2.66).
For solid brain metastases specifically, we calculated a mean time span from diagnostic MRI to
pre-treatment of MRI of 15.88 days (SD ± 6.33). In this time, in solid masses we observed a change in the
mean size of greatest dimension of 0.69cm (SD ± 0.69) to a mean of 1.27cm (SD ± 0.73). In volume,
solid masses grew from a mean of 1.12mL (SD ± 2.17) to a mean of 1.47mL (SD ± 3.00).
For necrotic brain metastases specifically, we calculated a mean time span from diagnostic MRI
to pre-treatment of MRI of 28.46 days (SD ± 25.58). In this time, in necrotic masses we observed a
change in the mean size of greatest dimension of 1.46cm (SD ± 0.79) to a mean of 1.74cm (SD ± 0.60). In
volume, necrotic masses grew from a mean of 1.44mL (SD ± 1.62) to a mean of 2.71mL (SD ± 1.86).
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In our sample population, we only observed one lesion that we characterized as cystic. The
timespan between diagnostic MRI to pre-treatment MRI was 24 days. In this time, the cystic lesion
developed from a size of greatest dimension of 1.87cm to 1.74cm. In volume, the cystic mass developed
from 1.99mL to 2.39mL.
Growth rates were calculated for the total of these metastases. When studying the size of greatest
dimension, the average rate of development for all masses was 0.12mm/day (SD ± 0.23). When studying
the total volume of each mass, the average rate of development for all masses was 0.03mL/day (SD ±
0.06).
Growth rates were also calculated for individual types of metastases, including the distinctions of
solid, necrotic, and cystic. Solid lesions were represented the most, as 24/38 (64.1%) of our lesions were
designated as solid during review of images. By size of greatest dimension, solid lesions developed at an
average rate of 0.12mm/day (SD ± 0.17). By volume, solid lesions developed at a rate of 0.02mL/day (SD
± 0.07).
Necrotic lesions were the second most common brain metastases in this study, making up 13/38
(34.2%) of the lesions observed during review of imaging. By size of greatest dimension, necrotic lesions
developed at an average rate of 0.13mm/day (SD ± 0.25). By volume, necrotic lesions developed at a rate
of 0.04mL/day (SD ± 0.04).
Only one cystic lesion was studied included in our sample population. This cystic lesion
represented 1/38 lesions (2.6%) of tumors observed, vastly less than the other types observed in this
study. This lesion grew at an average rate of 0.05mm/day by size of greatest dimension. By volume, this
lesion grew at an average rate of 0.02mL/day.
Expansion of margins was performed using diagnostic MRIs, and then compared with pretreatment MRI to observe extent of coverage. Of the lesions observed, 20 of the 38 masses, or 52.63%,
would be covered on pre-treatment MRI by a 2-mm expansion of diagnostic MRI lesion margins over the
average of 20.39 days (SD ± 16.54).
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Discussion
Of the results obtained in this study, perhaps the most important is the percentage of lesions
covered with 2-mm expansion of margins 20.39 days (SD ± 16.54). 52.63% is concerning, particularly for
patients who require Cyberknife since these plans may be determined >1 week in advance, unlike Gamma
Knife where treatment plans are determined from a pre-treatment MRI immediately before therapy. This
proved our null hypothesis to be incorrect and showed that many lesions did outgrow their 2-mm
expansion of margins between imaging sets. This growth is an important measure to quantify in patients
undergoing Cyberknife therapy to improve the confidence of radiation oncologists in their treatment plans
and ensure adequate coverage of lesions.
Our research has shown preliminary growth rates for brain metastases and aimed to classify
growth rates by type of lesion, including solid, necrotic, and cystic. When looking at our data, the average
rate of development for all masses was 0.12mm/day (SD ± 0.23). By total volume of each mass, the
average rate of development for all masses was 0.03mL/day (SD ± 0.06). It is difficult at this time to
compare growth rates of these different classifications due to the small sample size used in this study. One
aspect of our results that is important to discuss is the variability in growth rates observed our research. It
is evident that growth rates are not uniform amongst growth rates in even the same classifications of brain
metastasis used in this study. This makes the clinical relevance, which is based on predictability and
expected growth, difficult to ascertain from our early research.
Despite best efforts, some limitations with this study are present. The most prominent limitation
is the small sample size used in this study. Our study included 21 patients that were found to have brain
metastases on diagnostic MRI. Brain metastases come from a variety of primary cancer sources, have
variable growths, different locations in the brain, different amounts, and variable positioning in the brain.
All these factors make it difficult our small sample size of 21 patients to truly assess a general growth rate
of brain metastases. A larger sample size could broaden the applicability of this research in provide
clinicians with more generalizable approach.
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While a broad and general rule for the growth rate of brain metastases would be useful, it would
also be optimal to determine an expected growth rate of lesions based on the primary cancer source and
type. A larger sample size would also address this, by including enough patients of a specific primary
cancer to potentially extrapolate a suspected growth rate. This would enable radiation oncologists to
better understand the effects of delay in radiation treatment of different primary cancers. It would also
improve the utility of expansion of margins for brain metastases of specific cancers in an evidence-based
manner.
In addition to primary cancer types, a larger sample size can also better elucidate the growth rates
of different types of brain metastases, specifically solid, necrotic, and cystic distinctions. In the patients
observed in our study, there was only one patient with cystic brain metastases. This made it difficult to
assess the growth rates of this type of brain lesion. Along with the type of brain metastasis, better
understanding of the effect of location on the growth rate would also be beneficial in determining optimal
treatment strategy.
Another limitation of this study is the large ranges of data collected. For example, the delay
between diagnostic and pre-treatment MRI has great variability in our study. This may be a result of the
community served by Cooper University Hospital, where patients often have poor follow-up and thus do
not receive timely treatment. The large variability in delay in treatment make it difficult to assess how
quickly changes develop in normal settings, where treatment delay is typically ≤2 weeks, and often less.
A larger sample size may have helped to reduce the variability observed.
Determining margins of the lesions can be a somewhat subjective process and introduce bias.
This is another limitation of this study. Efforts were made to minimize the total observers to maintain
consistency in results. In some cases, it was necessary to collaborate to determine proper margins. This
was particularly necessary in cases where the lesion was not well defined, significant edema was present,
or the area of the lesion made it difficult to ascertain proper margins.
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Conclusion
This study was important in its’ function as a start for research into the growth rate of brain
metastases. This is significant for radiation oncology as it may aid in the development of treatment plans
for patients, determine which patients (particularly poor performance patients) may not benefit from
radiation treatment by using the expected growth as determined by growth rates, and point towards a
maximum imaging to treatment delay that has not yet been established.
Our research shows that at 20.39 days (SD ± 16.54), roughly 52.63% of patients were not covered
by 2-mm margins. This number is clearly concerning, and treatment delay should be <20 days to ensure
prevention of enlargement of brain metastasis and proper margin expansion during treatment planning.
The proper treatment delay is still not well-defined, but our evidence adds support to Seymour et al’s16
research that >14 days is likely too long of delay and is detrimental to a patient’s survival outcomes.
This research also showed preliminary growth rates of different types of brain metastases. From
the data we have collected, it is difficult to ascertain differences in these rates per tumor type due to the
small sample size. When looking at the growth rates of the entire body of brain metastases studied, the
average growth rate by size of greatest dimension was 0.12mm/day (SD ± 0.23). By volume, this resulted
in a growth rate of 0.03mL/day (SD ± 0.06). As discussed, the major limitation of this study is the small
sample size. Given the large variability in growth rates between brain metastases, a larger sample size
would help to establish greater confidence in the results and narrow the expected growth rate for these
lesions, making for greater clinical relevance and predictability.
Areas of future research should be directed towards learning growth rates of brain metastases
from different primary sources, an incredibly important criterion for developing a treatment algorithm.
This study can function as a starting point for further research in this area. A larger study with a greater
sample size will be required to determine more particular rates. After generalizing rates for location of
primary cancer, research can be further subdivided into different types of cancer from a given source. For
example, brain metastases from non-squamous cell carcinoma (NSCLC) may have a different growth rate
if its etiology is an epidermal growth factor receptor (EGFR) mutation. It may also be dependent on cell
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type, for example a squamous cell carcinoma versus an adenocarcinoma. It also may depend on the grade
of the cancer and the extent of anaplastic changes. Subdividing the growth rates of brain metastases in this
function would be more easily applicable and could develop a standardized protocol for determination of
treatment planning and margins. The goal would be for an algorithmic approach to determining expected
growth over a period of time.
Finally, growth rates could then be further subdivided based on location of lesion. Growth rates
may differ for areas of varying vascular supply. Brain metastases are known to distribute in areas of
increased vascular supply, likely due to their hematogenous spread, and may grow faster in these areas.4,5
Certain cancers have been known to metastasize to specific areas of the brain, and a correlation may exist
between primary source and vascular supply.4,5,6
This is an exciting avenue of radiation oncology research that has the potential to change how
care is broadly administered by radiation oncologists. Studying and learning the growth rate of brain
metastases may provide answers on reasonable treatment delay and prognosis. It also has the potential to
change how poor performance patients are treated to improve quality of life and ensure best care.

Tables and Figures:
Table A:
All masses
Number of masses
Days observed
Size of greatest dimension (in centimeters)
Size of volume (in milliliters)
Growth Rate by greatest dimension (in mm/day)
Growth Rate by volume (in mL/day)

Solid
38

Diagnostic MRI
Pre-treatment MRI
Diagnostic MRI
Pre-treatment MRI

20.39 (SD ± 16.54)
1.23cm (SD ± 0.73)
1.45 (SD ± 0.71).
1.27mL (SD ± 1.92)
1.92 (SD ± 2.66)
0.12 (SD ± 0.23)
0.03 (SD ± 0.06)

Necrotic
24

15.88 (SD ± 6.33)
0.69cm (SD ± 0.69)
1.27cm (SD ± 0.73)
1.12mL (SD ± 2.17)
1.47mL (SD ± 3.00)
0.12 (SD ± 0.17)
0.02 (SD ± 0.07)

Cystic
13

28.46 (SD ± 25.58)
1.46cm (SD ± 0.79)
1.74cm (SD ± 0.60)
1.44mL (SD ± 1.62)
2.71mL (SD ± 1.86)
0.13 (SD ± 0.25)
0.04 (SD ± 0.04)

1
24
1.87
1.74
1.99
2.39
0.05
0.02
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